VPC-3033

• Description :

  VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC50: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC50=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002) [1].

• UNSPSC :

  12352005

• Target :

  Androgen Receptor

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Field of Research :

  Cancer; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/vpc-3033.html

• Smiles :

  O=C1C2=C(/C(C3=C1C=CC=C3)=C\C4=CC(O)=CC=C4)C=CC=C2

• Molecular Formula :

  C21H14O2

• Molecular Weight :

  298.33

• References & Citations :

  [1]Li H, et al. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer[J]. Molecular cancer therapeutics, 2013, 12 (11) : 2425-2435.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [110763-24-1]